Download MendeleyDesign and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Fensome, A., Ambler, C.M., Arnold, E., Banker, M.E., Clark, J.D., Dowty, M.E., Efremov, I.V., Flick, A., Gerstenberger, B.S., Gifford, R.S., Gopalsamy, A., Hegen, M., Jussif, J., Limburg, D.C., Lin, T.H., Pierce, B.S., Sharma, R., Trujillo, J.I., Vajdos, F.F., Vincent, F., Wan, Z.K., Xing, L., Yang, X., Yang, X.(2020) Bioorg Med Chem 28: 115481-115481
- PubMed: 32253095
- DOI: https://doi.org/10.1016/j.bmc.2020.115481
- Primary Citation of Related Structures:
6VNS, 6VNV, 6VNX, 6VNY, 6W8L - PubMed Abstract:
Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.
Organizational Affiliation:
Medicine Design, Pfizer Inc, 1 Portland Street, Cambridge, MA 02139, United States. Electronic address: Andrew.Fensome@Pfizer.Com.
